Nocturnal urinary 6‐sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age‐matched controls and shows negative correlation with tumor‐size
- 1 September 1997
- journal article
- research article
- Published by Wiley in Journal of Pineal Research
- Vol. 23 (2) , 53-58
- https://doi.org/10.1111/j.1600-079x.1997.tb00335.x
Abstract
Bartsch C, Bartsch H, Karenovics A, Franz H, Peiker G, Mecke D. Nocturnal urinary 6‐sulphatoxymelatonin excretion is decreased in primary breast cancer patients compared to age‐matched controls and shows negative correlation with tumor‐size. J. Pineal Res. 1997; 23:53–58. © Munksgaard, Copenhagen In previous studies a tumor‐size dependent decline of the circadian amplitude of serum melatonin was found in primary unoperated breast cancer patients, which was not due to changes of the hepatic metabolism of melatonin since its main peripheral metabolite, 6‐sulphatoxymelatonin (aMT6s), showed similar serum levels. The aim of the current study was to verify these previous results by measurements of the nocturnal excretion of aMT6s in urine. The determination of aMT6s was carried out by radioimmunoassay. 17 primary unoperated breast cancer (BC) patients and 34 age‐matched control patients with different types of benign gynecological diseases awaiting operation (breast diseases, n=13; ovarian diseases, n=12; and uterine diseases, n=9) were analysed. The median nocturnal urinary aMT6s excretion (22:00–6:00 hr) was significantly lower (‐48%, P =0.033) in BC patients than in controls. Controls showed a significant negative linear regression with age (r = ‐0.419, P= 0.014). According to multivariate linear regression analysis, BC revealed no age‐dependency but a significant negative effect of increasing tumor‐size on aMT6s‐excretion (P= 0.036) was detected. These results confirm previous findings of a decreased pineal melatonin secretion in BC patients as well as an inverse relationship with tumor‐size excluding a possible distortion due to age. The mechanisms involved are unknown but indicate that BC may lead to an impaired production of pineal melatonin. The clinical relevance of these findings from therapeutic and diagnostic point of view is discussed.Keywords
This publication has 16 references indexed in Scilit:
- Melatonin concentrations in pineal organ culture are suppressed by sera from tumor-bearing miceJournal of Pineal Research, 1994
- Diminished Pineal Function Coincides with Disturbed Circadian Endocrine Rhythmicity in Untreated Primary Cancer Patients.Annals of the New York Academy of Sciences, 1994
- Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: Evidence for reduced pineal activity and relevance of urinary determinationsClinica Chimica Acta; International Journal of Clinical Chemistry, 1992
- Depression of serum melatonin in patients with primary breast cancer is not due to an increased peripheral metabolismCancer, 1991
- Stage-dependent depression of melatonin in patients with primary breast cancer. Correlation with prolactin, thyroid stimulating hormone, and steroid receptorsCancer, 1989
- Plasma Melatonin Levels in Patients Suffering From Colorectal CarcinomaJournal of Pineal Research, 1988
- Radioimmunoassay for 6-Sulphatoxymelatonin in Urine Using an Iodinated TracerAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1988
- Urinary melatonin levels in human breast cancer patientsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1981
- Effects of growing tumours on pineal melatonin levels in male ratsJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1981
- ROLE OF PINEAL GLAND IN qTIOLOGY AND TREATMENT OF BREAST CANCERThe Lancet, 1978